Original Article
Title
Increased PK11195-PET binding in the normal appearing white matter in
clinically isolated syndrome
Paolo Giannetti, MD,1 Marios Politis, MD, PhD,1,2 Paul Su, MSc,1 Federico Turkheimer,3
PhD, Omar Malik, MD, PhD,1 Shiva Keihaninejad, PhD,1 Kit Wu, MD,1 Adam Waldman,
PhD1, Richard Reynolds, PhD,1 Richard Nicholas*, MD, PhD,1 and Paola Piccini*, MD,
PhD1.
* These senior authors contributed equally to this study
1
Centre for Neuroinflammation and Neurodegeneration, Faculty of Medicine, Imperial
College London, Hammersmith Campus, Du Cane Road, London, W12 0NN, United
Kingdom.
2
Neurodegeneration Imaging Group, Department of Clinical Neuroscience, King’s College
London, De Crespigny Park, London, SE5 8AF, United Kingdom.
3
Centre for Neuroimaging, Institute of Psychiatry, King's College London, De Crespigny
Park, London, SE5 8AF, United Kingdom.
Correspondence to: Dr. Paolo Giannetti, 4th Floor, Burlington Danes Building,
Hammersmith Campus, Du Cane Road, London, W12 0NN, UK. Tel.: +44-(0)20 7594 6657;
Fax: +44-(0)20 7594 6548; email: p.giannetti@imperial.ac.uk
1
Running title: PK11195-PET in NAWM in CIS
Number of words in abstract: 295 words
Number of words in main text: 3,294 words
Number of figures: 6
Number of tables: 2
2
Summary
The most accurate predictor of the subsequent development of multiple sclerosis in clinically
isolated syndrome is the presence of lesions at MRI. We used in vivo PET with [11C]-(R)PK11195, a biomarker of activated microglia, to investigate the normal appearing white
matter and grey matter of subjects with clinically isolated syndrome to explore its role in the
development of multiple sclerosis. Eighteen clinically isolated syndrome and 8 healthy
control subjects were recruited. Baseline assessment included: history, neurological
examination, expanded disability status scale, MRI and PK11195-PET scans. All assessments
except the PK11195-PET scan were repeated over 2 years. SUPERPK methodology was used
to measure the binding potential relative to the non-specific volume, BPND. We show a global
increase of normal appearing white matter PK11195 BPND in clinically isolated syndrome
subjects compared to healthy controls (p=0.014). Clinically isolated syndrome subjects with
T2 MRI lesions had higher PK11195 BPND in normal appearing white matter (p=0.009) and
their normal appearing white matter PK11195 BPND correlated with the expanded disability
status scale (p=0.007; r=0.672). At two years those who developed dissemination in space or
multiple sclerosis, had higher PK11195 BPND in normal appearing white matter at baseline
(respectively p=0.007 and p=0.048). Central grey matter PK11195 BPND was increased in
clinically isolated syndrome subjects compared to healthy controls but no difference was
found in cortical grey matter PK11195 BPND. Microglial activation in clinically isolated
syndrome normal appearing white matter is diffusely increased compared to healthy controls
and is further increased in those who have MRI lesions. Furthermore microglial activation in
clinically isolated syndrome normal appearing white matter is also higher in those subjects
who developed multiple sclerosis at 2 years. Our finding, if replicated in a larger study, could
be of prognostic value and aid early treatment decisions in clinically isolated syndrome.
3
Keywords: multiple sclerosis; clinically isolated syndrome; microglia; normal appearing
white matter; PK11195-PET.
Abbreviations: CIS = Clinically Isolated Syndrome; CNS = Central Nervous System; MS =
Multiple Sclerosis; WM = White Matter; NAWM = Normal Appearing White Matter; GM =
Grey Matter; PK11195 = [(11)C](R)-PK11195; HC = Healthy Control; EDSS = Expanded
Disability Status Scale; ROI = Region-Of-Interest; BPND = Binding Potential of the
specifically bound radioligand relative to the Non-Displaceable radioligand in tissue; SD =
Standard deviation; MAPER = Multi-Atlas Propagation with Enhanced Registration; K-S =
Kolmogorov-Smirnov test; DIS = Dissemination In Space; DIT = Dissemination In Time;
TSPO = Translocator Protein.
Introduction
Clinically isolated syndrome (CIS) is a single episode of central nervous system (CNS)
dysfunction suggestive of focal demyelination (Miller et al., 2008). In those diagnosed with
multiple sclerosis (MS) CIS represents the disease onset in ~80% (Richards et al., 2002).
However, only 61% of CIS subjects developed clinical symptoms consistent with MS after 20
years, but those that do develop MS by 5 years will already have a higher disability (Chard et
al., 2011). This outcome indicates that there are likely underlying factors in those who will
get further symptoms consistent with MS and subsequently develop disability.
The most accurate predictor of MS development in CIS is the presence of brain lesions in the
white matter (WM) on MRI (Brex et al., 2002). In 107 CIS patients followed up for ~20
years 82% with an abnormal baseline MRI scan versus 21% with a ‘normal’ baseline MRI
4
developed MS (Fisniku et al., 2008). This suggests that a more general effect is active in
areas without lesions – the normal appearing WM (NAWM), which might act as a trigger to
the development of lesions (Linker et al., 2009). In CIS grey matter (GM) atrophy is also
reported (Dalton et al., 2004, Calabrese et al., 2011) both in cortical regions and deep GM.
Neuropathological, biochemical and imaging studies have shown abnormalities within the
NAWM in MS (Bjartmar et al., 2001, Graumann et al., 2003, Wheeler et al., 2008, AboulEnein et al., 2010), the most prominent of which is the occurrence of microglial clusters
around microvessels associated with increased expression of immune markers (De Groot et
al., 2001) and axonal changes (Howell et al., 2010), not visible on conventional MRI scans.
Significantly lower total N-acetyl-aspartate concentrations have been demonstrated in the
NAWM and were predictive of conversion to MS (Wattjes et al., 2008, Stromillo et al.,
2013), whereas other MRI measures thus far have not been consistently abnormal or
independently predictive of the development of MS (Brex et al., 1999, Fernando et al., 2005).
[11C]-(R)-PK11195 (PK11195) PET scanning offers a method to visualise in vivo tissue
changes, predominantly microglial and macrophage activation (Banati et al., 2000), derived
either from increased cell number or activation level, in the brain. PK11195-PET has been
used in MS to show inflammation within lesions (Banati et al., 2000, Debruyne et al., 2003,
Versijpt et al., 2005, Vas et al., 2008) and cortical GM PK11195-PET activity correlates with
disability (Politis et al., 2012). Given the possibility of generalised NAWM dysfunction and
the potential importance of microglial clusters in MS, we utilised PK11195-PET scanning to
identify whether there were any abnormalities within the NAWM in CIS and, given the prior
evidence of GM PK11195-PET in MS, whether there was any activity in the GM.
Furthermore, if present, we were interested to understand whether any changes could
potentially help refine the identification of subjects presenting with CIS who are at high risk
of MS and future disability.
5
Materials and methods
Study population and assessment
The study received Hammersmith and Queen Charlotte’s Research Ethics Committee ethical
approval and Administration of Radioactive Substances Advisory Committee permission to
administer PK11195. On receiving fully informed consent according to the Declaration of
Helsinki, subjects with a diagnosis of CIS defined as a subject presenting with a single
clinical episode suggestive of CNS demyelination, as well as healthy controls (HCs) were
recruited. All participants attended for a PK11195-PET scan and a co-localizing gadolinium
enhancing MRI scan within 7 days of each other. Patients were followed up yearly for 2
years. At each visit subjects were interviewed and the expanded disability status scale
(EDSS) (Kurtzke, 1983) was performed, and conversion to McDonald defined MS was
assessed (Polman et al., 2011).
MRI and PK11195-PET imaging
A clinical 1.5-Tesla MRI system (Siemens MAGNETOM Avanto) was used. Volumetric T1
weighted sequences (coronal and axial T1-spin echo: TR=635 ms, TE=17 ms, 5 mm slice
thickness); T1 volumetric magnetization-prepared rapid acquisition with gradient echo
(MPRAGE, TR=1900 ms, TE=3.53 ms, TI=1100 ms, flip angle 15°, 1 mm isotropic voxels)
pre- and post intravenous administration of gadobutrol (7.5 mmol) and T2-weighted
sequences (axial T2-spin echo: TR=4540 ms, TE=97 ms, 5 mm slice thickness; Axial FLAIR:
TR=9000 ms, TE=114 ms, TI=2500 ms, 5 mm slice thickness) were acquired for image
registration and to define regions of interest (ROIs). MRI images were re-orientated with the
6
horizontal line defined by the anterior – posterior commissure line and the sagittal planes
parallel to the midline.
For the PET scanning a Discovery RX PET/CT scanner was used. Images were reconstructed
with the ramp filter using the reprojection algorithm, acquiring a spatial resolution at 1 cm for
2D and 3D respectively of 4.8 mm and 5.8 mm FWHM, at 10 cm from the centre of
respectively 6.3 mm and 6.5 mm (Kemp et al., 2006). The CT images were used for
attenuation correction.
PK11195 was administered as an intravenous bolus; the tracer was injected over 10 s then
flushed with saline solution over 20 s. Emission data generated 18 time frames of tissue data
over 60 min (30 s background frame, 1 x 15 s frame, 1 x 5 s frame, 1 x 10 s frame, 1 x 30 s
frame, 4 x 60 s frames, 7 x 300 s frames, and 2 x 600 s frames). PK11195 tracer was supplied
by Hammersmith Imanetplc, London.
PK11195-PET analyses
Quantification of PK11195-PET data was carried out adopting the simplified reference region
model (Gunn et al., 1997) that uses a reference tissue input function and applies a simplified
one tissue compartment model to each pixel of the dynamic volume to generate a parametric
map of binding potential relative to the non-specific volume (BPND) (Innis et al., 2007). The
tissue reference input was extracted from the emission dynamic using the SUPERPK
software (Imperial Innovations) (Turkheimer et al., 2007, Yaqub et al., 2012). The reference
region is selected by modelling each pixel kinetic as the weighted sum of 4 tissue classes,
normal grey and white matter, vascular and microglia binding, the latter identified from the
striatum and globus pallidum of patients with clinically manifest Huntington’s disease. The
reference region is then calculated as the weighted average of the pixel grey matter indexes
7
across the whole brain. The method has been extensively validated against the gold-standard
plasma input function and across centres (Turkheimer et al., 2007, Yaqub et al., 2012).
PK11195-PET and MRI images were then automatically co-registered using the SPM2
software package (Functional Imaging Laboratory, Wellcome Department of Imaging
Neuroscience, UCL).
Analysis of Regions of Interest
ROIs were manually drawn within lesional WM and NAWM using the ANALYZE software
(version 8.1, Mayo Foundation) to generate maps for each subject. WM lesions were MRIdefined as T2-FLAIR hyperintensity identified by an experienced neuroradiologist (AW) and
a neurologist (PG). NAWM was defined as non-lesional WM, ROIs were drawn as far as
possible from WM lesions (>1cm). NAWM ROIs were sampled in all subjects with a mean
(±SD) volume of 1.75 (±0.88) cm3. GM was automatically segmented (SPM2 software) and
ROIs maps generated using the multi-atlas propagation with enhanced registration (MAPER)
approach (Heckemann et al., 2010). Manually drawn and MAPER generated maps were then
used to calculate the volume and the BPND of PK11195 for each ROI.
Statistical Analyses
Statistical analyses were performed using SPSS (Version 17.0) and PRISM (GraphPad
Software, Inc. Version 6.01 for Windows). For all the variables, the normality of the
distribution was tested with the Kolmogorov-Smirnov test (K-S), while the Shapiro-Wilk test
was used for small samples (n<5). If normality was satisfied, bivariate correlation was tested
using Pearson correlation coefficient. If normality was not satisfied, the Spearman's rho
correlation coefficient was used. Differences between two groups were tested using the
8
Independent Samples T-Test, corrected when equal variance was not assumed (Welch’s
correction), according to the Levene’s test for the equality of variance. When the assumption
of normality was not satisfied, the difference between two groups was tested using the
Independent Samples Mann-Whitney U Test. K-S was also used to compare population
distributions. The general linear model for repeated measures was used to analyse the
variance of within-subjects variables and between-subjects factors. The Greenhouse-Geisser
correction was then used to test the ROIxGroup interaction (given the significant Mauchly’s
test of sphericity).
Results
CIS: clinical onset, MRI T2 WM lesions and outcome at two years
Eighteen CIS subjects (Table 1) and 8 HCs (mean age of 30.2 (±5.5) years, 5 female) were
recruited. The CIS clinical presentation was a spinal cord syndrome in 8, brainstem syndrome
in 7, optic neuritis in 2 and one a hemispheric lesion. Sixteen subjects completed the 2 year
follow-up, two patients withdrew because they felt they had no problems. At 2 years 13
patients presented with the radiological criteria for dissemination in space (DIS), 13 for
dissemination in time (DIT) and 12 had MS, as defined in 2010 McDonald criteria (Polman et
al., 2011). Five patients had a second relapse satisfying the criteria for clinically-defined MS.
As with previous reports (Fisniku et al., 2008, Chard et al., 2011) baseline MRI T2 lesion
number and volume in subjects who developed MS at 2 years was increased compared to
those subjects who had no further symptoms (Table 2). This was significant for both the
number of MRI T2 lesions (p=0.016) and the MRI T2 volume in our study population
(p=0.012). As expected, in T2 lesions the PK11195 BPND was higher than in NAWM,
respectively 0.153 (±0.095) and 0.078 (±0.027) (p=0.0096).
9
The BPND of PK11195 is globally increased within the NAWM of CIS subjects
To assess whether there were any differences in the NAWM PK11195 BPND between CIS
subjects and HCs (Fig. 1), we initially considered the mean NAWM PK11195 BPND for each
subject, and found PK11195 BPND was significantly increased in CIS subjects compared to
HCs (p=0.024, Fig. 2a). Given that the PK11195 BPND is measured in multiple ROIs we
compared the NAWM PK11195 BPND distribution over all the ROIs studied and found that in
CIS the NAWM PK11195 BPND was significantly different compared to HCs (p<0.0001, Fig.
2b). Using repeated measures with ROI as the repeated factor and Group as a between subject
factor we found a significant increase in NAWM PK11195 BPND in the CIS Group compared
to the HC group (p=0.014, Fig. 2c). The increased PK11195 BPND in NAWM did not show
any significant ROI effect (p=0.414), implying a diffuse global change. There was no ROI
effect evident when the clinical symptom onset was considered.
Presence of MRI T2 lesions in CIS is associated with increased global PK11195
BPND change in NAWM, which correlates with disability
Giving the known importance of T2 MRI lesions in prognosis of CIS, both in terms of
developing MS and disability, we explored whether the presence of WM lesions was
associated with higher PK11195 BPND in the NAWM. We found that mean NAWM
PK11195 BPND per subject was significantly increased in those CIS subjects with lesions
compared to those without lesions (p=0.017, Fig. 3a). To exclude any effect from the
multiple ROIs measured, we again utilised repeated measure testing between two groups
(group 1: CIS with lesions vs group 2: CIS without lesions) and found a significant increase
in the CIS group with lesions compared to those without lesions (p=0.009, Fig. 3b),
10
independent of the ROI repeated factor (p=0.414) implying a diffuse global change. The
relevance of T2 lesions is further supported by the finding that in CIS subjects with lesions
there was a significant correlation (p=0.007; r=0.673) between the BPND of PK11195 in
NAWM and disability score (EDSS, Fig. 3c).
CIS subjects who develop MS at 2 years have increased NAWM BPND of PK11195
at baseline
Given that those with CIS have an increased risk of developing MS, we tested the difference
in mean NAWM PK11195 BPND in each subject between those who developed MS at 2 years
and those who did not. Mean NAWM PK11195 BPND per subject was increased in those who
developed MS at 2 years (p=0.04), whereas those who did not develop MS had PK11195
BPND signal levels similar to HC (Fig. 4a). Further analysis found that this significant
increase in mean PK11195 BPND was evident in the group who fulfilled the criteria for DIS
(p=0.014) but not for the group who fulfilled the criteria for DIT (p=0.207). Again we
confirmed that these findings were a diffuse global change by utilising repeated measures
with ROI as the repeated factor and Group as a between subject factor in the NAWM
PK11195 BPND in CIS who developed MS at the 2-year follow-up. We found that NAWM
PK11195 BPND was increased in the CIS group who developed MS (p=0.048, ROI effect
p=0.612) and that this was related to the group who satisfied the DIS criteria (DIS+ vs DISp=0.007, ROI effect p=0.369) and not the DIT criteria (p=0.308). Thus, the baseline
PK11195 BPND activity in NAWM was significantly higher in CIS subjects who
subsequently developed MS and who satisfied the DIS criteria but not DIT criteria (Fig. 4b).
GM central structures show a higher PK11195 BPND in CIS
11
In contrast to the findings in the WM, there were no differences in the GM PK11195 BPND
between CIS subjects and HCs in the mean GM PK11195 BPND (CIS 0.112 ±0.080 and HCs
0.121 ±0.079), its distribution within the ROIs studied and in the cortical GM. However, in
the central GM structures (Fig. 5) PK11195 BPND was significantly higher in CIS than HC,
both using repeated measures for Group effect (p=0.028, with no ROI effect p=0.136) than
the subjects’ average (p=0.006, Fig. 6).
The presence of MRI T2 lesions were not associated with any differences in cortical GM
PK11195 BPND (with MRI T2 lesions 0.092 (±0.064); without MRI T2 lesions 0.100
(±0.062), p=0.588)) but MRI T2 lesions were associated with increased central GM structure
PK11195 BPND (with MRI T2 lesions 0.208 (±0.059); without MRI T2 lesions 0.173
(±0.051), group effect p=0.049, with no ROI effect p=0.635). However, there was no
associated GM PK11195 BPND difference in those who were diagnosed with MS at 2 years
compared to those who were not.
Discussion
In this study PK11195-PET has been used to investigate a surrogate marker of microglia
activation, TSPO expression, in the NAWM and the GM of CIS subjects. NAWM PK11195
BPND is globally increased in CIS compared to HCs at baseline and interestingly this increase
was concentrated in those who had MRI T2 lesions at baseline imaging. Consistent with the
known association of T2 lesions and the increased subsequent risk of MS, those who went on
to develop McDonald defined MS at 2 years had higher global NAWM PK11195 BPND at
baseline. In the cortical GM there was no difference in PK11195 BPND between CIS and
HCs. However, the central GM PK11195 BPND was increased in CIS compared to HCs.
12
PK11195 has proved particularly useful as a PET tracer because of its favourable dynamics
and kinetics; it is a high affinity TSPO ligand and has the ability to cross the blood brain
barrier (Schweitzer et al., 2010) with a well established methodology for quantification
(Turkheimer et al., 2007, Yaqub et al., 2012) and its binding is not affected by the known
polymorphism in the TSPO gene that affects other ligands (Owen et al., 2011). In both MS
and experimental autoimmune encephalomyelitis (EAE) tissues PK11195 binding was found
to be consistently and strongly coupled with microglial activation (Shah et al., 1994,
Vowinckel et al., 1997, Banati et al., 2000, Venneti et al., 2008). Given the potential role of
areas of activated microglial clustering (van Horssen et al., 2012) that are not visible to MR
imaging, we utilised PK11195-PET as a biomarker to determine if there was any evidence of
microglial activation in the NAWM of CIS subjects.
This group, followed-up clinically and with MRI for 2 years, had a high rate of conversion to
McDonald confirmed MS (12 converted vs 4 who did not convert). However, because two
were lost to follow-up as they felt well this would make them a typical CIS population (Chard
et al., 2011). The finding that in CIS there is a global increase in NAWM microglial
activation, would be consistent with the presence of underlying areas of the NAWM that
might be predisposed to lesion formation in which clusters of activated microglia are present
(van Horssen et al., 2012) together with diffuse changes to axons and nodes of Ranvier
(Howell et al., 2010). The increase is more prominent in those who had MRI T2 lesions at
baseline and this group is known to have a higher risk of developing MS than those with no
MRI T2 lesions (Fisniku et al., 2008, Chard et al., 2011). Consistent with this, in our
population higher levels of NAWM PK11195 BPND were associated with a higher risk of
developing MS at 2 years predominantly through subsequent dissemination in space. This
could suggest, if confirmed in further studies, that the underlying change in the NAWM
increases the risk of a WM lesion developing.
13
Alterations in brain homeostasis can cause microglial activation in normal appearing brain
tissue (van Horssen et al., 2012) and does not necessarily indicate irreversible damage or
even impaired function of underlying brain tissue. In addition, it is possible that microglial
activation in the NAWM is a protective response to inflammation (Graumann et al., 2003,
Heppner et al., 2005). However, the increase in NAWM PK11195 BPND seen in subjects with
MRI T2 WM lesions was correlated with the EDSS which might suggest, in our limited
population that in subjects with WM lesions the NAWM is already affected and associated
with an impaired neuronal function. The association of higher microglia activity in NAWM
and clinical disability was not present at 2 years. This could indicate that any impaired
neuronal function was temporary, however due to the exploratory nature of the study
PK11195-PET was not repeated at this point, thus this interpretation represents only one
possible explanation. Is well known that microglial activation in the WM is associated with
more aggressive MS (Kutzelnigg et al., 2005) and it is possible to inhibit microglial
activation at the early stages of EAE, and this has a beneficial effect on the final clinical
outcome (Heppner et al., 2005, Bhasin et al., 2007).
In CIS patients studied here, the GM in the central structures showed higher PK11195 BPND
compared to HCs. Thalamic atrophy is known to be present in CIS and early MS (Cifelli et
al., 2002, Calabrese et al., 2011, Langkammer et al., 2013) and increased PK11195-PET
activity in the thalamus has been reported (Banati et al., 2000). However, the increased
PK11195-PET activity in the thalamus has not been reported in CIS before, but would be
consistent with the MRI thalamic atrophy seen in CIS. Cortical GM PK11195 BPND was not
increased in CIS compared to HCs. We have previously shown using the same methods that
there was increased cortical GM PK11195 BPND in MS, and that this correlated with
disability (Politis et al., 2012). The lack of any elevation in cortical GM PK11195 BPND in
CIS could be because PK11195-PET is not sensitive enough to detect any changes despite
14
our detection of changes in deep GM PK11195 BPND. Cortical GM atrophy has been found
on MRI (Dalton et al., 2004) in CIS and this could indicate that cortical GM atrophy might
precede microglial activation and with microglial activation becoming more prominent in the
cortex as the condition progresses.
In conclusion, we report widespread microglial activation in the NAWM in CIS. Higher
levels of microglial activation were seen in those CIS subjects with WM lesions on MRI at
baseline and in those who subsequently who developed MS. However, the relatively small
population and the lack of a follow-up PK11195-PET scan represent limitations and further
work is required to understand the persistence of the abnormal NAWM activation and how
NAWM activation compares to MRI in predicting future development of MS.
Figure Legends
Figure 1
Normal appearing white matter (NAWM) on PK11195-PET images co-registered and fused
with MRI of three subjects of our population. The first subject is a HC (A) with PK11195
BPND in NAWM of 0.028; the second is a CIS subject without T2 MRI lesions (B), an
expanded disability status scale (EDSS) score of 3.5 and PK11195 BPND in NAWM of 0.037;
the third is a CIS subject with T2 MRI lesions (C), EDSS=2.0 and PK11195 BPND in NAWM
of 0.136. The colour scale bar represents the BPND of PK11195.
Figure 2
15
Global changes in normal appearing white matter (NAWM) in clinically isolated syndromes
(CIS) subjects compared to healthy controls (HC). Inset A shows the average of PK11195
BPND for each subject represented by a black dot (HC PK11195 BPND average in NAWM is
0.042, while is 0.071 in CIS subjects). The inset B shows the significant difference in
NAWM regions frequency distribution (Y axis, percentage) according to their PK11195
BPND (X axis) between HC and CIS. There is a higher percentage of NAWM regions with
low PK11195 BPND in HC (in blue, left side of the graph) than CIS (in red, right side of the
graph) Inset C shows the significant group effect studied using repeated measures with
NAWM regions of interest as the repeated factor and Group (HC in blue; CIS in red) as a
between subject factor.
Figure 3
Global changes in normal appearing white matter (NAWM) in clinically isolated syndromes
(CIS) subjects without T2 white matter (WM) lesions at MRI scan compared to CIS subjects
with T2 WM lesions. Inset A shows the average of PK11195 BPND for each subject
represented by a black dot (CIS without WM lesions PK11195 BPND average in NAWM is
0.032, while is 0.078 in CIS subjects with WM lesions). The inset B shows the significant
group effect studied using repeated measures with NAWM regions of interest as the repeated
factor and Group (CIS without WM lesions in green; CIS with WM lesions in red) as a
between subject factor. Inset C shows the significant correlation between PK11195 BPND (Y
axis) and Expanded Disability Status Scale (EDSS, X axis) in CIS with WM lesions
(r=0.673); dotted lines represent error bars.
16
Figure 4
Baseline PK11195 BPND in normal appearing white matter (NAWM) of healthy controls
(HC) and clinically isolated syndromes (CIS) who remained CIS or were diagnosed with
multiple sclerosis (MS) at the 2-year follow-up (FU). Inset A shows the average of PK11195
BPND for each subject represented by a black dot (HC PK11195 BPND average in NAWM is
0.042, CIS PK11195 BPND average in NAWM is 0.045, while is 0.080 in CIS subjects who
developed MS at 2-year FU). On the Y axis of inset B are listed the 16 subjects who
completed the 2-year FU ordered according to their NAWM PK11195 BPND value (X axis) at
the baseline PK11195-PET scan. The green colour represent the dissemination in space (DIS,
present in 13 subjects); in red the dissemination in time (DIT, present in 13 subjects). Patients
who developed both DIS and DIT, hence diagnosed with multiple sclerosis (MS, 12 subjects)
according to the 2010 revision of McDonald criteria for MS diagnosis, are therefore MS
labelled on the Y axis. In blue the subjects who remained at the CIS stage and did not
develop both DIS and DIT.
Figure 5
Coronal section of central structures on PK11195-PET images coregistred and fused with
MRI of two subjects of our population. The first subject is a healthy volunteer (A) with
PK11195 BPND in GM central structures of 0.163; the second is a clinically isolated
syndrome (CIS) subject (B), EDSS=4.0 and PK11195 BPND in GM central structures of
0.248. The colour scale bar represents the BPND of PK11195.
Figure 6
17
Baseline PK11195 BPND in central structure of healthy controls (HC) and clinically isolated
syndromes (CIS) subjects. This figure shows the average of PK11195 BPND for each subject
represented by a black dot (HC PK11195 BPND average in central structures is 0.167, while is
0.197 in CIS subjects).
Funding
PG thanks the EFNS (European federation of neurological Societies) for a Scientific
Fellowship in 2009, the FISM (Fondazione Italiana Sclerosi Multipla) for a training
(research) fellowship, (Cod. 2010/B/7) and MSTC (Multiple Sclerosis Trials Collaboration).
FT received a MRC PET Methodology Grant G1100809/1. RN was supported by the
National Institute for Health Research (NIHR) Imperial Biomedical Research Centre. The
views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or
the Department of Health.
References
Aboul-Enein F, Krssák M, Höftberger R, Prayer D, Kristoferitsch W. Reduced NAA-levels in
the NAWM of patients with MS is a feature of progression. A study with quantitative
magnetic resonance spectroscopy at 3 Tesla. PLoS ONE. 2010;5:e11625.
Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F, et al. The
peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo
imaging of microglia as a measure of disease activity. Brain. 2000;123:2321-37.
18
Bhasin M, Wu M, Tsirka SE. Modulation of microglial/macrophage activation by
macrophage inhibitory factor (TKP) or tuftsin (TKPR) attenuates the disease course of
experimental autoimmune encephalomyelitis. BMC Immunology. 2007;8:10.
Bjartmar C, Kinkel RP, Kidd G, Rudick RA, Trapp BD. Axonal loss in normal-appearing
white matter in a patient with acute MS. Neurology. 2001;57:1248-52.
Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal
study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med.
2002;346:158-64.
Brex PA, Gomez-Anson B, Parker GJ, Molyneux PD, Miszkiel KA, Barker GJ, et al. Proton
MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis. Journal of
the Neurological Sciences. 1999;166:16-22.
Calabrese M, Rinaldi F, Mattisi I, Bernardi V, Favaretto A, Perini P, et al. The predictive
value of gray matter atrophy in clinically isolated syndromes. Neurology. 2011;77:257-63.
Chard DT, Dalton CM, Swanton J, Fisniku LK, Miszkiel KA, Thompson AJ, et al. MRI only
conversion to multiple sclerosis following a clinically isolated syndrome. J Neurol Neurosurg
Psychiatr. 2011;82:176-9.
Cifelli A, Arridge M, Jezzard P, Esiri MM, Palace J, Matthews PM. Thalamic
neurodegeneration in multiple sclerosis. Ann Neurol. 2002;52:650-3.
Dalton CM, Chard DT, Davies GR, Miszkiel KA, Altmann DR, Fernando K, et al. Early
development of multiple sclerosis is associated with progressive grey matter atrophy in
patients presenting with clinically isolated syndromes. Brain. 2004;127:1101-7.
De Groot CJ, Bergers E, Kamphorst W, Ravid R, Polman CH, Barkhof F, et al. Post-mortem
MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active
demyelinating and (p)reactive lesions. Brain. 2001;124:1635-45.
19
Debruyne JC, Versijpt J, Van Laere KJ, De Vos F, Keppens J, Strijckmans K, et al. PET
visualization of microglia in multiple sclerosis patients using [11C]PK11195. Eur J Neurol.
2003;10:257-64.
Fernando KTM, Tozer DJ, Miszkiel KA, Gordon RM, Swanton JK, Dalton CM, et al.
Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple
sclerosis. Brain. 2005;128:2911-25.
Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, et al. Disability
and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.
Brain. 2008;131:808-17.
Graumann U, Reynolds R, Steck AJ, Schaeren-Wiemers N. Molecular changes in normal
appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms
against hypoxic insult. Brain Pathol. 2003;13:554-73.
Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligandreceptor binding in PET using a simplified reference region model. Neuroimage. 1997;6:27987.
Heckemann RA, Keihaninejad S, Aljabar P, Rueckert D, Hajnal JV, Hammers A. Improving
intersubject image registration using tissue-class information benefits robustness and
accuracy of multi-atlas based anatomical segmentation. Neuroimage. 2010;51:221-7.
Heppner FL, Greter M, Marino D, Falsig J, Raivich G, Hövelmeyer N, et al. Experimental
autoimmune encephalomyelitis repressed by microglial paralysis. Nature Medicine.
2005;11:146-52.
Howell OW, Rundle JL, Garg A, Komada M, Brophy PJ, Reynolds R. Activated microglia
mediate axoglial disruption that contributes to axonal injury in multiple sclerosis. Journal of
Neuropathology and Experimental Neurology. 2010;69:1017-33.
20
Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus
nomenclature for in vivo imaging of reversibly binding radioligands. Journal of Cerebral
Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood
Flow and Metabolism. 2007;27:1533-9.
Kemp BJ, Kim C, Williams JJ, Ganin A, Lowe VJ. NEMA NU 2-2001 performance
measurements of an LYSO-based PET/CT system in 2D and 3D acquisition modes. J Nucl
Med. 2006;47:1960-7.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status
scale (EDSS). Neurology. 1983;33:1444-52.
Kutzelnigg A, Lucchinetti CF, Stadelmann C, Brück W, Rauschka H, Bergmann M, et al.
Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain.
2005;128:2705-12.
Langkammer C, Liu T, Khalil M, Enzinger C, Jehna M, Fuchs S, et al. Quantitative
susceptibility mapping in multiple sclerosis. Radiology. 2013;267:551-9.
Linker R, Gold R, Luhder F. Function of neurotrophic factors beyond the nervous system:
inflammation and autoimmune demyelination. Crit Rev Immunol. 2009;29:43-68.
Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, et al.
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Multiple
Sclerosis (Houndmills, Basingstoke, England). 2008;14:1157-74.
Owen DRJ, Gunn RN, Rabiner EA, Bennacef I, Fujita M, Kreisl WC, et al. Mixed-affinity
binding in humans with 18-kDa translocator protein ligands. J Nucl Med. 2011;52:24-32.
Politis M, Giannetti P, Su P, Turkheimer F, Keihaninejad S, Wu K, et al. Increased PK11195
PET binding in the cortex of patients with MS correlates with disability. Neurology.
2012;79:523-30.
21
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic
criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol.
2011;69:292-302.
Richards RG, Sampson FC, Beard SM, Tappenden P. A review of the natural history and
epidemiology of multiple sclerosis: implications for resource allocation and health economic
models. Health Technology Assessment (Winchester, England). 2002;6:1-73.
Schweitzer PJ, Fallon BA, Mann JJ, Kumar JSD. PET tracers for the peripheral
benzodiazepine receptor and uses thereof. Drug Discovery Today. 2010;15(21-22):933-42.
Shah F, Hume SP, Pike VW, Ashworth S, McDermott J. Synthesis of the enantiomers of [Nmethyl-11C]PK 11195 and comparison of their behaviours as radioligands for PK binding
sites in rats. Nuclear Medicine and Biology. 1994;21:573-81.
Stromillo ML, Giorgio A, Rossi F, Battaglini M, Hakiki B, Malentacchi G, et al. Brain
metabolic changes suggestive of axonal damage in radiologically isolated syndrome.
Neurology. 2013;80:2090-4.
Turkheimer FE, Edison P, Pavese N, Roncaroli F, Anderson AN, Hammers A, et al.
Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J Nucl Med.
2007;48:158-67.
van Horssen J, Singh S, van der Pol S, Kipp M, Lim JL, Peferoen L, et al. Clusters of
activated microglia in normal-appearing white matter show signs of innate immune
activation. J Neuroinflammation. 2012;9:156.
Vas A, Shchukin Y, Karrenbauer VD, Cselényi Z, Kostulas K, Hillert J, et al. Functional
neuroimaging in multiple sclerosis with radiolabelled glia markers: preliminary comparative
PET studies with [11C]vinpocetine and [11C]PK11195 in patients. Journal of the
Neurological Sciences. 2008;264:9-17.
22
Venneti S, Wang G, Nguyen J, Wiley CA. The positron emission tomography ligand
DAA1106 binds with high affinity to activated microglia in human neurological disorders.
Journal of Neuropathology and Experimental Neurology. 2008;67:1001-10.
Versijpt J, Debruyne JC, Van Laere KJ, De Vos F, Keppens J, Strijckmans K, et al.
Microglial imaging with positron emission tomography and atrophy measurements with
magnetic resonance imaging in multiple sclerosis: a correlative study. Multiple Sclerosis
(Houndmills, Basingstoke, England). 2005;11:127-34.
Vowinckel E, Reutens D, Becher B, Verge G, Evans A, Owens T, et al. PK11195 binding to
the peripheral benzodiazepine receptor as a marker of microglia activation in multiple
sclerosis and experimental autoimmune encephalomyelitis. Journal of Neuroscience
Research. 1997;50:345-53.
Wattjes MP, Harzheim M, Lutterbey GG, Bogdanow M, Schild HH, Träber F. High field MR
imaging and 1H-MR spectroscopy in clinically isolated syndromes suggestive of multiple
sclerosis: correlation between metabolic alterations and diagnostic MR imaging criteria.
Journal of Neurology. 2008;255:56-63.
Wheeler D, Bandaru VVR, Calabresi PA, Nath A, Haughey NJ. A defect of sphingolipid
metabolism modifies the properties of normal appearing white matter in multiple sclerosis.
Brain. 2008;131:3092-102.
Yaqub M, van Berckel BN, Schuitemaker A, Hinz R, Turkheimer FE, Tomasi G, et al.
Optimization of supervised cluster analysis for extracting reference tissue input curves in (R)[(11)C]PK11195 brain PET studies. Journal of cerebral blood flow and metabolism: official
journal of the International Society of Cerebral Blood Flow and Metabolism. 2012;32:16008.
23
24